Gelonghui March 12丨Dongyangguang Changjiang Pharmaceutical (01558.HK) announced that, based on the Group's currently available unaudited management accounts and preliminary estimates from the company's management, the main financial data are as follows:
1. For the year ended 31 December 2023, the Group expects to record a turnover of approximately RMB 6.295 billion, an increase of approximately 68.09% over the same period last year of approximately RMB 3,745 billion;
2. For the year ended 31 December 2023, the Group expects to record profit before tax of approximately RMB 2,027 billion to RMB 2,227 billion, an increase of approximately 5,097.44% to 5,610.26% compared with the profit before tax recorded in the same period last year of approximately RMB 39 million;
3. For the year ended 31 December 2023, the Group expects to record net profit to mother of approximately RMB 1,900 billion to RMB 210 billion. Compared with the same period last year, net profit to mother was approximately RMB 77 million, an increase of about 2367.53% to 2627.27%.
It is expected that this increase is mainly due to the gradual improvement in social and economic performance, the trend of normalization of personnel movements and daily social activities, and the Group's strengthening of academic promotion and brand building this year. Brand awareness of the Group's core product Kewei has further increased, and all other pipeline businesses have shown good performance. The overall business has shown a common development trend of multiple product lines.